A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy

BACKGROUND: Co-stimulatory receptor agonist antibodies have shown promising antitumor efficacy in preclinical models. However, their clinical development lags due to systemic or local adverse effects of non-specific T cell activation. Utilization of a bispecific antibody format to reduce off-tumor i...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Jie, Zhang, Huihui, Huang, Yue, Fan, Lilv, Li, Fanlin, Li, Min, Yan, Yaping, Zhang, Junshi, Li, Zeyu, Yang, Xuanming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8434866/
https://www.ncbi.nlm.nih.gov/pubmed/34522140
http://dx.doi.org/10.2147/CMAR.S330637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8434866/
https://www.ncbi.nlm.nih.gov/pubmed/34522140
http://dx.doi.org/10.2147/CMAR.S330637

Ejemplares similares